- Weak Dollar Is Golden for Mining Companies
- How Many US Consumers Will Shop this Weekend?
- Tuesday's Heavy Dose of Data to Dictate 'Risk' Behavior
- World's Largest Share Issue Priced at Deep Discount
- GE Capital Losses May See Dramatic Fall: JP Morgan
- Obama says Boosting US Jobs is Top Priority
- Why the Dollar Will Likely Stay Weak for Some Time
- Playboy to Outsource Most Magazine Operations: Report
- General Motors to Cut up to 9,500 Jobs in Europe
- Can Murdoch Help Bing Challenge Google and Shift the Content Equation?
- HP's Mark Hurd
- HP Comes in As Expected; Is It Time to Buy?
- 9 Stocks That Play Rising Water Costs: Strategists
- Weis' Deal Likely Won't Change Big Money Contracts
- Gold Prices Can Double in 3 Years: Portfolio Manager
- Nov. 23: Unusual Volume Leaders
- Help Wanted—Please Run $4 Billion University
- Apple Comes to AT&T's Rescue
- GlaxoSmithKline pulls swine flu vaccines in Canada
- Medtronic 2Q profit rises 59 percent on sales
- SAfrican recession ends with 3rd quarter growth
- A year later, scale of UK bank bailout revealed
- Medvedev orders probe into lawyer's prison death
- Heinz 2Q profit falls, but sales improve
- Ahead of the Bell: Consumer Confidence
- China, EU to discuss protectionism, climate change
- BMO Financial to buy Diners Club N. American ops
NeurogesX gets FDA approval for pain patch
Text Size 
SAN MATEO, Calif. - Biotechnology company NeurogesX Inc. said Monday it received Food and Drug Administration approval for its Qutenza pain patch.
The regulatory approval is for postherpetic neuralgia, a type of nerve pain condition that results from shingles. The patch is already approved in Europe for peripheral nerve pain in non-diabetic adults.
NeurogesX plans to launch Qutenza in the United States through its own sales force in the first half of 2010.
Shares of NeurogesX rose 76 cents, or 9.2 percent, to $9 in after-hours trading after falling 4 cents to close at $8.24 during the regular trading session.
Copyright 2009 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
Print
Email
- A diet high in fat and sugar might actually be good for your portfolio.
- Warren Buffett and Bill Gates discuss the economy and other subjects with CNBC's Becky Quick.
- From the AIG&T to the Merrill Lychee, Jane Wells lists this year's fashionable holiday cocktails.
- One shopper explains why – aside from the prices – he gets up at 3am on the day after Thanksgiving to go shopping every year.
- Congressman Ron Paul explains to Squawk Box why he’s pushing legislation to audit the Federal Reserve.
- …you'll want to be prepared. Tips for getting the most out of the post-Thanksgiving shopping frenzy.
Data is a real-time snapshot *Data is delayed at least 15 minutes